MS related employment and disease modifying treatment in the German working population: 1994-2009.
Relapses in MS may affect the acquisition and maintenance of employment due to associated neurological deficits. Several disease modifying drugs (DMD) like interferons or glatiramer reduce the frequency of relapses and decrease their severity in MS. To investigate the influence of DMD on employment prevalence and employment rate with relapsing remitting Multiple Sclerosis (RR-MS) in the German working population from 1994 to 2009. Database assessment of working patients with MS and German labour market statistic database. Four DMD have been introduced in Germany for the treatment of RR-MS during the observation time: Interferon beta-1b (Betaferon) was approved 1996 whereas interferon beta-1a has been available in intramuscular formulation since 1997 (Avonex) and subcutaneous formulation since 1998 (Rebif). The non-interferon glatiramer (Copaxone) was introduced in 2001. Both general employment and employment with MS have increased during this period. The employment increase with RR-MS was higher than in general population only after the availability of all four DMD during the time period 2002-2009 (p = 0.008). The overall mean employment prevalence of RR-MS subjects was 0.82 ± 0.03 among 1,000 workers. The annual prescription volume of all DMD rose every year since their introduction until the end of our observation of about 10% annually. Employment increases among RR-MS patients highly correlated with the time frame of DMD availability (correlation rate 0.88, p < 0.0001). The employment rate with DMD was higher than without treatment (p < 0.0001). The introduction of DMD may have positively influenced the employment with MS.